Back to search

Netherlands· NL-4f11e8721fd9

Menveo, oplossing voor injectie

A meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert product, registered in Netherlands by GlaxoSmithKline Vaccines S.r.l.. The same ATC class is registered in 11 of our 19 countries.

ATC J07AH08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMenveo, oplossing voor injectieATCJ07AH08REGISTER NO.NL-4f11e8721fd9PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.

Countries holding a registration under ATC J07AH08 (meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AH08

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Manufacturer
GlaxoSmithKline Vaccines S.r.l.
Country
Netherlands (NL)
ATC code
J07AH08
ATC class
Meningokokken A, C, Y, W-135, tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/10/614

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eec6402e-181e-4f97-a450-cda7a667f90d
GET /v1/drugs/eec6402e-181e-4f97-a450-cda7a667f90d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Intramusculair gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/menveo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131686",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP A GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
    "MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP C GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
    "MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP W135 GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
    "MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP Y GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/09/19",
  "procedure_number": "EMEA/H/C/001095",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/10/614",
  "additional_monitoring": "N"
}

See everything about meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.